Исторические, патогенетические и клинические аспекты перитонэктомии у больных канцероматозом брюшины Medline.ru - медико-биологический информационный портал Медлайн.ру

1.Sugarbaker P.H. Peritonectomy procedures. Annals of surgery. 1995;221(1):29-42.

2. Sugarbaker P.H. Peritonectomy procedures. Cancer Treat Res.1996;82:235-253.

3. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Mongr. 1975;42:101-104.

4. Hacker N.F., Berek J.S., Lagasse L.D., et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983; 61(4):413-420.

5. Joyeux H., Szawlowski A.W., Saint-Aubert B., et al. Aggressive region surgery for advanced ovarian carcinoma. Cancer. 1986;57(1):142-147.

7. Fujimura T., Yonemura Y., Fujita H., et al. Dual Arterial Infusion Chemotherapy, Continuous Hyperthermic Peritoneal Perfusion, and Total Parietal Peritonectomy for Peritoneal Dissemination in Gastric Cancer. Gan to Kagaku Ryoho. 1994; 21(13): 2335-2337.

8. Averbach A.M., Sugarbaker P. Recurrent Intrabdominal Cancer with Intestinal Obstruction. Int Surg. 1995;80(2):141-146.

9. Fujimura T., Yonemura Y, Nakagawara H, et al. Chemohyperthermic Peritoneal Perfusion and Subtotal Peritonectomy for Peritonitis Carcinomatosa in Gastroenteric Cancer. Gan to Kagaku Ryoho. 1995;22 (11):1610-1612.

10. Sugarbaker P. Complete Parietal and Visceral Peritonectomy of Pelvis for Advanced Primary and Recurrent Ovarian Cancer. Cancer Treat Res. 1996;81:75-87.

11. Sugarbaker P. Management of peritoneal surface malignancy using intoperitoneal chemotherapy and cytoreductive surgery. Langenbecks Arch Surg. 1999; 384(6):576-587.

12. Sugarbaker P. Result of treatment of 385 patients with peritoneal surface of appendiceal malignancy. Ann Surg Oncol. 1999;6(8):727-731.

13. Sugarbaker P. Its what the surgeon doesn?t see that kills the patient. J Nippon Med Sch. 2000;67(1):5-8.

14. Pestieau S.R., Esquivel J., Sugarbaker P. Pleura extension of mucinous tumor in patient with pseudomyxoma peritonei syndrome. Ann Surg Oncol. 2000;7(3):199-203.

15. Fujimura T. Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritoneal carcinomatosa in gastrointestinal cancer. Oncol Rep. 2000; (4):809-814.

16. Esquivel J., Sugarbaker P. Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg. 2001;234(2):198-205.

17. Sugarbaker P. Managing the peritoneal surface component of gastrointestinal cancer: Part 1. Oncology (Williston Park). 2004;18(1):51-59.

18. Sugarbaker P. Managing the peritoneal surface component of gastrointestinal cancer: Part 2. Oncology (Williston Park). 2004;18(2):207-219.

19. Weiss L. Metastatic inefficiency: Causes and consequence. Cancer Rev. 1986;3:1-24.

20. Perez J., Rodriguez M.J., Campana O., et al. Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients. Rev Esp Anestesiol Reanim. 2006;53(9):550-555.

21. Satani M., Oomae N., Tomita A., et al. Blood transfusion for massive hemorrhage associated with scheduled peritonectomy for pseudomyxoma peritonei and peritoneal dissemination. Masui. 2009;58(4):432-437.

22. Saxena A., Yan T.D., Morris D.L. Critical assessment of preoperative and operative risk factors for complications after iterative peritonectomy procedures. Eur J Surg Oncol. 2010;36(3):309-314.

23. Baratti Dario, Shigeki Kusamura, Antonello Domenico Cabras, Marcello Deraco. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Annals of surgical oncology. 2012;19(5):1416-1424.

24. Tsilimparis N., Bockelmann C., Raue W., et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk?. Ann Surg Oncol. 2013;20(1):226-232.

25. Adrian Bartos, Dana Bartos, Stoian Raluca, et al. Cytoreductive Surgery and Hyperthermic intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis: Our Intial Experience. Chirurgia. 2019;114(2):222-233.

26. Alzahrani N, Ferguson JS, Valle SJ, Liauw W, Chua T, Morris DL. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: long-term result at St George Hospital, Australia. ANZ J Surg. 2016;86(11):937-941.

27. Arjona-Sanchez A., Rufain-Pena S., Artiles M., et al. Residual tumour less than 0.25 centimeters and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic Chemotherapy. Int J Hyperthermia. 2018;34(5):570-577.

28. Nagata H., Ishihara S., Hata K., et al. Survival and prognostic factors for methachronous peritoneal metastasis in patients with colon cancer. Ann Surg Oncol. 2017;24(5):1269-1280.

29. Sugarbaker P, Sardi A, Brown G, Dromain C, Rousset P, Jelinek JS. Concering CT features used to select patients for treatment of peritoneal metastases, a pictoral assay. Int J Hyperthermia. 2017;33(5):497-504.

30. Izquierdo F., Sherman S.K., Schuitevoerder D., Turga K.K. Modern surgical Techiques in cytoreductive surgery. J Gastrointest Surg. 2019;24(2):454-459.

31. Sugarbaker P. Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer. World J Surg. 1995;19(2):235-240.

32. Sugarbaker P. Intraperitoneal Chemotherapy and Cytoreductive Surgery for Prevention and Treatment of Peritoneal Carcinomatosis and Sarcomatosis. Semin Surg Oncol. 1998;14 (3):254-261.

33. Cotte E., Passot G., Gilly F.N., Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J. Gastrointest. Oncol. 2010;2(1):31-35.

34. Bozzetti F., Yu W., Baratti D., Kusamura S., Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol. 2008;98(4):273-276.

35. Verwaal V.J., van Tinteren H., Ruth S.V., Zoetmulder F.A. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004;85(2):61-67.

36. Elias D., Gilly F., Boutitie F., et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncl. 2010;28(1):63-62.

37. Шелехов А. В., Дворниченко В.В., Радостев С.И. и др. Циторедуктивные операции в лечении рака яичников 3С стадии: сравнительный анализ результатов //Вопросы онкологии. - 2019. - Т. 65. - 1. - С. 142-146.

38. Берлев И. В., Беляев А. М., Карачун А. М., и др. Циторедуктивные операции с перитонэктомией у больных раком яичников: технические аспекты и непосредственные результаты //Вопросы онкологии. - 2018. - Т. 64. - 3. - С. 345-352.

39. Koole S.N., van Driel W.J., Sonke G.S. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on. Cancer. 2019;125 suppl 24:4587-4593.

40. Yonemura Y., Canbay E., Li Y. et al. A comprehensive treat- ment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016;42(8):1123-1131.

41. Enblad M., Ghanipour L., Cashin P.H. Prognostic scores for colorectal cancer with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, International Journal of Hyperthermia. 2018;34(8):1390-1395.

42. Sugarbaker P. Second-look surgery for colorectal cancer: revised selection and new treatment options for greater success. Int J Surg Oncol. 2011:1-8.

43. Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer. 2020;127:76-95.

44. Harmon R.L., Sugarbaker P.H. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncca. 2005;2(1):1-10.

45. Kostić Z., Ćuk V., Bokun R., et al. Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma. Vojnosanitetski pregled. 2006;63(4):349-356.

46. Yonemura Y., Nojima N, Kaji M, et al. E‐cadherin and urokinase‐type plasminogen activator tissue status in gastric carcinoma. Cancer. 1995;76(6):941-953.

47. Jayne D.G., O'Leary R., Gill A., Hick A., et al. A three-dimensional in-vitro model for the study of peritoneal tumour metastasis. Clinical & experimental metastasis. 1999;17(6):515-523.

48. Jayne D.G. The molecular biology of peritoneal carcinomatosis from gastrointestinal cancer. Annals of the Academy of Medicine, Singapore. 2003;32(2):219-225.

49. Sacchi G., Di Paolo N., Venezia F., Rossi A., et al. Possible role of milky spots in mesothelial transplantation. The International journal of artificial organs. 2007;30(6):520-526.

50. Yonemura Y., Kawamura T., Bandou E., Tsukiyama G., et al. The natural history of free cancer cells in the peritoneal cavity. Advances in peritoneal surface oncology. - Springer, Berlin, Heidelberg, 2007:11-23.

51. Kusamura S., Baratti D., Zaffaroni N., Villa R., et al. Pathophysiology and biology of peritoneal carcinomatosis. World journal of gastrointestinal oncology. 2010;2(1):12-18.

52. Gu J., Roth L.M., Younger C., Michael H., et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. Journal of the National Cancer Institute. 2001;93(15):1147-1152.

53. Coccolini F., Gheza F., Lotti M., Virzì S., et al. Peritoneal carcinomatosis. World journal of gastroenterology. 2013;19(41):6979-6994.

54. Sinukumar S., Rajan F., Mehta S., Damodaran D., et al. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer-A study by INDEPSO. European Journal of Surgical Oncology. 2021;47(1):75-81.

55. De Lima Vazquez V, V Stuart O.A., Mohamed F., Sugarbaker P.H. et al. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer chemotherapy and pharmacology. 2003;52(2):108-112.

56. Günakan E., Tohma Y.A., Tunç M., Akıllı H., Şahin H., Ayhan A. Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer //Obstetrics & Gynecology Science. 2020;63(1):64-71.

57. Casado-Adam A., Alderman R., Stuart O.A., Chang D., Sugarbaker PH. Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol. 2011;2011:1-10.

58. Wiseman J.T., Kimbrough C., Beal E.W., et al. Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter? Ann Surg Oncol. 2020;27(3):783-792.

59. Youssef H., Newman C., Chandrakumaran K. et al. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Diseases of the Colon and Rectum. 2011;54(3):293-299.

60. Pelz J.O.W, Doerfer J., Decker M. et al. Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model. Int J Colorectal Dis. 2007;22(8):941-947.

61. Preti V., Chang D., Sugarbaker P.H. Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients. Gastroenterology research and practice 2012;2012:635314

62. Li X.B., Peng K.W., Ji Z.H. et al. Prevention of venous thromboembolism after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Development of a physiotherapy program. Clin Appl Thromb Hemost 2019;25:1076029619890415.

63. Rottenstreich A., Kalish Y., Kleinstern G. et al. Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2017;116(7):914-920.

64. Glehen O., Osinsky D., Cotte E., et al. Intraperitoneal Chemotherapy using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10(8):863-869.

65. Балюра О.В. Современные подходы к лечению острой кишечной непроходимости карциноматозного генеза в лечебных учреждениях Министерства обороны Российской Федерации: Дис. ...канд. мед. Наук: 14.01.17 Хирургия/ С.-петерб. ВмедА, 2012, 152.

66. Гринев М. В. Циторедуктивная хирургия. М.: «Гиппократ», 2003. - 92 с.

67. Доманский А. А., Карачун А. М., Абдукеримова А. Б., и др. Структура послеоперационных осложнений после перитонэктомии с мультиорганными резекциями и внутрибрюшной химиоперфузией у больных с перитонеальным канцероматозом / Сборник тезисов VI Петербургский международный онкологический форум «Белые ночи 2020»; Санкт-Петербург, 25-28 июня 2020 г. - Санкт-Петербург: Вопросы онкологии, 2020. - С. 27.

68. Сизоненко Н.А. Программа ускоренного выздоровления в хирургическом лечении больных острой обтурационной толстокишечной непроходимости опухолевого гененза: Дис. ...канд. мед. Наук: 14.01.17 Хирургия/ С.-петерб. ВмедА, 2019, 147.